TRxADE HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results

Rhea-AI Summary

TRxADE Health reported a 6% revenue increase to $3.2 million in Q1 2022, driven by its TRxADE and TRxADE Prime platforms. However, gross profit fell 4% to $1.3 million, reflecting rising costs. Operating expenses rose to $2.3 million, primarily due to IT initiatives and increased salaries. The net loss widened to $1.0 million, compared to $0.7 million a year ago. The company registered 339 new members, totaling approximately 13,475. Notably, processed sales volume on TRxADE Prime surged over 600%. Management remains optimistic about growth opportunities.

Positive

• Q1 2022 revenue increased 6% to $3.2 million.
• Registered members in TRxADE grew by 339 to over 13,475.
• Processed sales volume on TRxADE Prime rose over 600%.
• New unique buyers on TRxADE Prime increased by 184%.

Negative

• Gross profit decreased 4% to $1.3 million.
• Operating expenses rose to $2.3 million, up from $2 million.
• Net loss increased to $1.0 million from $0.7 million.
• Adjusted EBITDA worsened to ($0.7) million compared to ($0.5) million.

Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform

TAMPA, FL / ACCESSWIRE / May 9, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the 2022 first quarter (Q1) ended March 31, 2022.

First Quarter 2022 and Subsequent Operational Highlights

TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 339 new registered members in Q1 2022, bringing the total registered members to approximately 13,475+ at March 31, 2022.

TRxADE announced a venture with Exchange Health, LLC, SOSRx, LLC. SOSRx will provide pharmaceutical manufacturers a single platform to optimize the sale and distribution of their inventory directly to large pharmaceutical buyers across multiple classes of trade. SOSRx opens the market to short dated, over stock and slow-moving pharmaceuticals that would otherwise be subject to destruction. TRxADE anticipates growth in 2022 as more progressive manufacturers are expected to address the public need for enhanced medication accessibility and reliable supply of cost-effective pharmaceuticals.

Management Commentary

"I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms for the first quarter of 2022. We have continued to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities.

Our new venture, SOSRx, is an exciting addition that provides additional availability to short dated and overstocked drugs, with a goal to positively impact the public need for cost effective medication.

The TRxADE marketplace connects wholesalers and independent pharmacies and our SOSRx marketplace connects the manufacturers and wholesalers. Both the TRxADE and SOSRx marketplaces deliver radical price transparency, economies of scale and competition that benefit the independent pharmacies and wholesalers, while expanding the selling potential for such participants.

We believe the TRxADE and SOSRx platforms provide the opportunity to deliver more affordable prescription costs for consumers.

This is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our shareholders," concluded Mr. Suren Ajjarapu, the Company's Chairman and Chief Executive Officer.

First Quarter 2022 Financial Summary

Revenues for the first quarter of 2022, increased 6% to $3.2 million, compared to revenue of $3.1 million in the same quarter last year. The increase in revenue was primarily due to revenue generated by the TRxADE Platform and TRxADE Prime.

Gross profit in the first quarter of 2022, decreased 4% to $1.3 million, or 41% of revenues, compared to gross profit of $1.4 million, or 45% of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to higher costs associated with TRxADE Prime transactions.

Operating expenses in the first quarter of 2022 were $2.3 million, compared to $2 million in the same quarter last year. This increase is primarily due to continued IT initiatives and increased salary and legal expenses.

Net loss in the first quarter of 2022 was ($1.0) million, or ($0.12) per basic and diluted share outstanding, compared to a net loss of ($0.7) million, or ($0.08) per basic and diluted share outstanding, in the same quarter last year.

Adjusted EBITDA, a non-GAAP financial measure, decreased to ($0.7) million for the first quarter of 2022, compared to ($0.5) million in the same quarter last year.See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set forth at the end of this release.

Additional metrics related to our key performance are as follows:

As of March 31, 2022, the TRxADE Platform increased its registered users by 915 or 7.3% compared to March 31, 2021. For the quarter ended March 31, 2022, new registrations were 339 compared to 223 for the prior period in 2021. As of March 31, 2022, total registered users increased to 13,475 from 12,560 at March 31, 2021.

The table below summarizes the key metrics that management evaluated in relation to the activity on the TRxADE Platform for the three month period ended March 31, 2022 compared to the same period in 2021:

As of March 31, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime") increased processed sales volume over 600% and increased unique buyers on the TRxADE Prime platform by 184%.

The table below summarizes the key metrics that management evaluated in relation to the activity for TRxADE Prime for the three month period ended March 31, 2022, compared to the same period in 2021:

Conference Call and Webcast

Management will host a conference call on Monday, May 9, 2022, at 5:00 p.m. Eastern time to discuss TRxADE's first quarter 2022 financial results. The call will conclude with Q&A from participants. To participate, please use the following information:

Q1 2022 Conference Call and Webcast

Date: Monday, May 9, 2021
Time: 5:00 p.m. Eastern time
U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878
Conference ID: 13728738
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1541816&tp_key=cbf4963985

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

A playback of the call will be available through June 9, 2022. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13728738. A webcast will also be available for 30 days on the IR section of the TRxADE website or by clicking the webcast link above.

About TRxADE HEALTH, Inc.

TRxADE HEALTH, Inc. (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 13,475+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For more information on TRxADE Health, please visit the Company's IR website at investors.trxadehealth.com.

Use of Non-GAAP Financial Information

In addition to our results calculated under generally accepted accounting principles in the United States ("GAAP"), in this earnings release we also present EBITDA and Adjusted EBITDA which are "non-GAAP financial measures" presented as supplemental measures of the Company's performance. They are not presented in accordance with GAAP. EBITDA represents net income before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based compensation expense, litigation expense and loss (gain) on impairment of goodwill. EBITDA and Adjusted EBITDA are presented because we believe they provide additional useful information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA are also frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization are noncash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than TRxADE HEALTH, Inc. does, limiting its usefulness as a comparative measure. EBITDA and Adjusted EBITDA are not recognized in accordance with GAAP, are unaudited, and have limitations as analytical tools, and you should not consider them in isolation, or as substitutes for analysis of the Company's results as reported under GAAP. The Company's presentation of these measures should not be construed as an inference that future results will be unaffected by unusual or nonrecurring items. We compensate for these limitations by providing a reconciliation of each of these non-GAAP measures to the most comparable GAAP measure. We encourage investors and others to review our business, results of operations, and financial information in their entirety, not to rely on any single financial measure, and to view these non-GAAP measures in conjunction with the most directly comparable GAAP financial measure. For more information on these non-GAAP financial measures, please see the section titled "Reconciliation of Net Income attributable to TRxADE HEALTH, INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA", included at the end of this release.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks relating to agreements with third parties, including Coborn's; the planned benefits, expected users of, and projected revenues of our venture with Exchange Health; amounts we owe and may owe to Exchange Health in connection with the Joint Venture; security interests under certain of our credit arrangements; the fact that we are exploring strategic alternatives for our Bonum Health, Inc. subsidiary; our operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the Company's stock repurchase program; the adoption of the Company's product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; our ability to raise funding in the future, as and if needed, and the terms of such funding; increased inflation; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission (SEC), and more particularly in the Quarterly Report on Form 10-Q filed today with the SEC and our Annual Report on Form 10-K for the year ended December 31, 2021. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Investor Relations:

IR@trxade.com
Investors.trxadegroup.com

TRxADE HEALTH, INC.
Consolidated Balance Sheets
March 31, 2022, and December 31, 2021

		March 31,				December 31,
		2022				2021
Assets
Current Assets
Cash		$	1,870,682			$	3,122,578
Accounts Receivable, net			1,040,893				978,973
Inventory			273,950				56,279
Prepaid Assets			400,376				216,414
Undeposited funds			11,166				-
Total Current Assets			3,597,067				4,374,244
Property Plant and Equipment, Net			73,679				98,751
Intangible Asset, net			792,500				-
Other Assets
Deposits			49,031				60,136
Right of use Leased Assets			1,178,705				1,233,033
Research and Development			149,229				-
Total Assets		$	5,840,211			$	5,766,164
Liabilities and Stockholders' Equity
Current Liabilities
Accounts Payable			908,495				477,028
Accrued Liabilities			344,938				270,437
Current Portion Lease Liabilities			175,237				178,561
Customer Deposits			996				-
Notes Payable- Related Party			166,667				-
Total Current Liabilities			1,596,333				926,026
Long Term Liabilities
Notes Payable-Related Party			333,333				-
Other Long-Term Liabilities - Leases			1,022,967				1,069,965
Total Liabilities			2,952,633				1,995,991
Stockholders' Equity
Series A Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding, as of March 31, 2022 and December 31, 2021.
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 8,181,041 and 8,166,457 shares issued and outstanding, as of March 31, 2022 and December 31, 2021, respectively			82				82
Additional Paid-in Capital			20,083,269				20,017,528
Retained Deficit			(17,213,273	)			(16,247,437	)
Total TRxADE HEALTH, INC. stockholders' equity			2,870,078				3,770,173
Non-Controlling Interest			17,500				-
Total Stockholders' Equity			2,887,578				3,770,173
Total Liabilities and Stockholders' Equity		$	5,840,211			$	5,766,164

TRxADE HEALTH, INC.
Consolidated Statements of Operations
For the Three Months Ended March 31, 2022, and 2021
(unaudited)

		Three Months Ended March 31,
		2022				2021
Revenues		$	3,240,272			$	3,053,235
Cost of Sales			1,904,569				1,669,924
Gross Profit			1,335,703				1,383,311
Operating Expense
Wage and Salary Expense			1,069,958				939,634
Professional Fees			101,009				264,819
Accounting and Legal Expense			236,221				160,047
Technology Expense			245,785				214,890
General and Administrative			651,302				448,176
Total Operating Expenses			2,304,275				2,027,566
Operating Loss			(968,572	)			(644,255	)
Gain on Disposal of Asset			4,100				-
Interest Expense			(1,364	)			(7,264	)
Net Loss		$	(965,836	)		$	(651,519	)
Net loss attributable to TRxADE HEALTH, Inc.			(960,147	)			(651,519	)
Net loss attributable to non-controlling interests			(5,689	)			-
Net loss per Common Share - Basic and Diluted		$	(0.12	)		$	(0.08	)
Weighted average Common Shares Outstanding - Basic and Diluted			8,178,124				8,093,199

TRxADE HEALTH, INC.
Consolidated Statements of Cash Flows
For the Three months ended March 31, 2022, and 2021
(unaudited)

		2022				2021
Operating Activities:
Net Loss		$	(965,836	)		$	(651,519	)
Adjustments to reconcile net income (loss) to net cash used in Operating activities:
Depreciation Expense			3,972				1,750
Options Expense			32,783				75,738
Common Stock Issued for Services			32,083				98,247
Bad Debt Expense			1,317				-
Gain on sale of asset			(1,900	)			-
Amortization of Right of Use Assets			54,328				31,678
Changes in Operating assets and liabilities:
Other assets			(149,229	)			-
Accounts Receivable, net			(63,237	)			(1,131,807	)
Prepaid Assets			(172,857	)			(306,490	)
Inventory			(217,671	)			787,632
Undeposited Customer Funds			(11,166	)			-
Investment in Sub			-				6,425
Lease Liability			(50,322	)			(31,517	)
Accounts Payable			431,467				109,642
Accrued Liabilities			74,501				299,923
Customer Deposits			996				-
Net Cash Used in operating activities			(1,000,771	)			(710,298	)
Investing Activities:
Sale of Fixed Assets			23,000				-
Net Cash Provided by investing activities			23,000				-
Financing Activities:
Distributions to Non-Controlling Interest			(275,000	)			-
Proceeds from Exercise of Warrants			875				-
Net Cash Used in financing activities			(274,125	)			-
Net Increase (Decrease) in Cash			(1,251,896	)			(710,298	)
Cash at beginning of the Period			3,122,578				5,919,578
Cash at End of the Period		$	1,870,682			$	5,209,280
Supplemental Cash Flow Information
Cash Paid for Interest		$	1,364			$	1,639
Cash Paid for Income Taxes		$	-			$	-
Non-Cash Transactions
Insurance Premium Financed		$	220,354			$	-
Note Issued as SOSRx Contribution		$	500,000			$	-
Intangible Asset Contribution from Non-controlling interest		$	792,500			$	-

Reconciliation of Net Income (Loss) attributable to TRxADE HEALTH, INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA*

		For the three months ended March 31,
		2022				2021
Net Income (Loss) attributable to TRxADE HEALTH, INC.		$	(965,836	)		$	(651,519	)
Add (deduct):
Interest, net			1,364				7,264
Depreciation and amortization			3,971				1,750
EBITDA			(960,501	)			(642,505	)
Add (deduct):
Loss on Impairment of Goodwill			-				-
Litigation Expenses			225,000				-
Stock-based compensation			64,866				173,985
Adjusted EBITDA *		$	(670,635	)		$	(468,520	)

* EBITDA and Adjusted EBITDA are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. See also "Use of Non-GAAP Financial Information", above.

SOURCE: TRxADE HEALTH, INC.

View source version on accesswire.com:
https://www.accesswire.com/700429/TRxADE-HEALTH-Reports-First-Quarter-Revenue-Growth-of-6-and-Q1-2022-Financial-Results

FAQ

What were TRxADE Health's revenues in Q1 2022?

TRxADE Health reported revenues of $3.2 million in Q1 2022.

How did TRxADE's gross profit perform in Q1 2022?

Gross profit decreased by 4% to $1.3 million in Q1 2022.

What was TRxADE's net loss for the first quarter of 2022?

The net loss for Q1 2022 was $1.0 million.

How many new registered members did TRxADE add in Q1 2022?

TRxADE added 339 new registered members in Q1 2022.

What is the future outlook for TRxADE Health following the Q1 2022 results?

Management is optimistic about growth opportunities, particularly with the expansion of TRxADE and TRxADE Prime platforms.